Seminars in Oncology
Volume 30, Issue 1 , Pages 79-85 , February 2003

Targeting lethal minimal residual disease in small cell lung cancer

References 

  1. Ihde DC. Chemotherapy of lung cancer. N Engl J Med. 1992;327:1434–1441
  2. Sandler AB. Current management of small cell lung cancer. Semin Oncol. 1997;24:463–476
  3. Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330:827–838
  4. Pelosi G, Pasini F, Pavenel F, et al.  Effects of different immunolabeling techniques on the detection of small-cell lung cancer cells in bone marrow. J Histochem Cytochem. 1999;47:1075–1087
  5. Zippelius A, Pantel K. RT-PCR-cased detection of occult disseminated tumor cells in peripheral blood and bone marrow of patients with solid tumors. An overview. Ann N Y Acad Sci. 2000;906:110–123
  6. Peck K, Sher Y, Shih J, et al.  Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res. 1998;58:2761–2765
  7. Lacroix J, Becker HD, Woerner SM, et al.  Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preprogrp-specific RT PCR. Int J Cancer. 2001;92:1–8
  8. Bessho A, Tabata M, Kiura K, et al.  Detection of occult tumor cells in peripheral blood from patients with small cell lung cancer by reverse transcriptase polymerase chain reaction. Anticancer Res. 2000;20:1149–1154
  9. Leon S, Shapiro B, Sklaroff D, et al.  Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–650
  10. Stroun M, Anker P, Lyautey J, et al.  Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol. 1989;23:707–712
  11. Anker P, Mulcahy H, Chen X, et al.  Detection of circulating tumour DNA in blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 1999;18:65–73
  12. Anker P, Stroun M. Tumor-related alterations in circulation DNA, potential for diagnosis, prognosis and detection of minimal residual disease. Leukemia. 2001;15:289–291
  13. Gonzalez R, Silva J, Sanchez A, et al.  Microsatellite alterations and TP53 mutations in plasma DNA of small cell lung cancer patients: Follow up study and prognostic significance. Ann Oncol. 2000;11:1097–1104
  14. Hunt JD, Robert EG, Zieske AW, et al.  Orthotopic human lung carcinoma xenografts in BALB/c mice immunosuppressed with anti-CD4 monoclonal antibodies and chronic alcohol consumption. Cancer. 2000;88:468–479
  15. Hidalgo M, Siu L, Nemaunaitis J, et al.  Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267–3279
  16. Nawrocki B, Polette M, Marchand V, et al.  Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: Quantificative and morphologic analyses. Int J Cancer. 1997;72:556–564
  17. Michael M, Babic B, Khokha R, et al.  Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol. 1999;17:1802–1808
  18. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer–TIMP-1 as a prognostic marker. Anticancer Res. 2000;20:1311–1316
  19. Shepherd F, Giaccone G, Debruyne C. Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: An NCIC and EORTC study. In: Proceedings of the American Society of Clinical Oncology, San Francisco, CA. May 12-15, 2001; (abstr 1)
  20. Smylie M, Mercier R, Aboulafia D, et al.  Phase III study of the matrix metalloproteinase inhibitor prinomastat in patients having advanced non–small cell lung cancer. In: Proceedings of the American Society of Clinical Oncology, San Francisco, CA. May 12-15, 2001; (abstr 1226)
  21. Bissett D, Pawel JV, Mercier R, et al.  Phase III study of the matrix metalloproteinase inhibitor prinomastat in combination with gemcitabine and cisplatin in non–small cell lung cancer. In: Proceedings of the American Society of Clinical Oncology. Orlando, FL. May 17-21, 2002; (abstr 1183)
  22. Hirota S, Isozaki K, Moriyama Y, et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–580
  23. Heinrich M, Corless C, Blanke C, et al.  KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs). In: Proceedings of the American Society of Clinical Oncology, Orlando, FL. May 17-21, 2002; (abstr 6)
  24. Sekido Y, Obata Y, Ueda R, et al.  Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res. 1999;51:2416–2419
  25. Johnson B, Fisher B, Fisher T, et al.  A phase II study of STI571 (Gleevec) for patients with small cell lung cancer. In: Proceedings of the American Society of Clinical Oncology, Orlando, FL. May 17-21, 2002; (abstr 1171)
  26. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res. 1996;56:370–376
  27. Wang W, Healy M, Sattler M, et al.  Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI571. Oncogene. 2000;19:3521–3528
  28. Krystal GW, Honsawek S, Litz J, et al.  The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res. 2000;6:3319–3326
  29. Hamilton WB, Helling F, Livingston PO. Ganglioside expression on sarcoma and small cell lung carcinoma compared to tumors of neuroectodermal origin. Proc Am Assoc Cancer Res. 1993;34:491; (abstr)
  30. Zhang S, Cordon-Cardo C, Zhang H, et al.  Selection of tumor antigens as targets for immune attack using immunuhistochemistry: I. Focus on gangliosides. Int J Cancer. 1997;73:42–49
  31. Brezicka F-T, Olling S, Nilsson O, et al.  Immunohistological detection of Fucosyl-GM1 ganglioside in human lung cancer and normal tissues with monoclonal antibodies. Cancer Res. 1989;49:1300–1305
  32. Fuentes R, Allman R, Mason MD. Ganglioside expression in lung cancer cell lines. Lung Cancer. 1997;18:21–33
  33. Brezicka FT, Olling S, Bergman B, et al.  Coexpression of ganglioside antigen Fuc-GM1, neural-cell adhesion molecule, carcinoembryonic antigen, and carbohydrate tumor-associated antigen CA 50 in lung cancer. Tumor Biol. 1992;13:308–315
  34. Cheresh DA, Pierschbacher MD, Herzig MA, et al.  Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol. 1986;102:688–696
  35. Grant SC, Kostakoglu L, Kris MG, et al.  Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3f8: A pilot trial. Eur J Nucl Med. 1996;23:145–149
  36. Zhang S, Zhang HS, Cordon-Cardo C, et al.  Selection of tumor antigens for immune attack using immunohistochemistry: III. Protein antigens. Clin Cancer Res. 1998;4:2669–2676
  37. Bhattacharya-Chatterjee M, Chatterjee S, Foon K. The anti-idiotypic vaccines for immunotherapy. Curr Opin Molec Ther. 2001;3:63–69
  38. McCaffery M, Yao T-J, Williams L, et al.  Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant. Clin Cancer Res. 1996;2:679–686
  39. Grant SC, Kris MG, Houghton AN, et al.  Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res. 1999;5:1319–1323
  40. Macher BA, Pacuzska T, Mullin BR, et al.  Isolation and identification of a fucose-containing ganglioside from bovine thyroid gland. Biochim Biophys Acta. 1979;588:35–43
  41. Fredman P, Brezicka T, Holmgren J, et al.  Binding specificity of monoclonal antibodies to ganglioside, Fuc-GM1. Biochim Biophys Acta. 1986;875:316–323
  42. Vangsted AJ, Clausen H, Kjeldsen TB, et al.  Immunochemical detection of a small cell lung cancer-associated ganglioside (FucGM1) antigen in serum. Cancer Res. 1991;51:2879–2884
  43. Yoshino H, Ariga T, Latov N, et al.  Fucosyl-GM1 in human sensory nervous tissue is a target antigen in patients with autoimmune neuropathies. J Neurochem. 1993;61:658–663
  44. Dickler MN, Ragupathi G, Liu NX, et al.  Immunogenicity of a Fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res. 1999;5:2773–2779
  45. Krug LM, Ragupathi G, Livingston P, et al.  Pilot trial of a synthetic fucosyl-GM1 ganglioside vaccine in patients with small cell lung cancer. In: Proceedings of the American Society of Clinical Oncology, Orlando, FL. May 17-21, 2002; (abstr 1824)

☆ Address reprint requests to Lee M. Krug, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021.

PII: S0093-7754(03)70045-1

doi: 10.1053/sonc.2003.50018

Seminars in Oncology
Volume 30, Issue 1 , Pages 79-85 , February 2003

Article Tools